Helsinn announces launch of oral formulation of Akynzeo in China

Helsinn

9 June 2020 - Helsinn announces launch of oral formulation of Akynzeo in China.

Helsinn is pleased to announce that the oral formulation of Akynzeo for the treatment of chemotherapy-induced nausea and vomiting has been launched in China.

Helsinn’s partner Mundipharma has exclusive marketing, promotion and sale rights for the oral formulation of Akynzeo in China. Helsinn is responsible for supplying the drug and co-detailing the product in Shanghai while retaining all international development rights, including clinical development activities.

Read Helsinn press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Market access , China